LUCENTIS (Genentech)

← Back to Medical Devices, Pharma & Biotech BS Detector Get Business Strategy

Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech

Generic Claims: advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes…

Red Flags: FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified…

Semantic Drift Patterns: homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…

Proof Expectations: specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations…

(https://lucentis.com) 📸 Data Snapshot: May 31, 2026

Analyze the raw signals below. How would a machine score this business’s credibility?

Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.

🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)

HOMEPAGE LUCENTIS® (ranibizumab) a Treatment Option for wAMD, DR & DME, mCNV, & RVO (https://lucentis.com)

Title

LUCENTIS® (ranibizumab) a Treatment Option for wAMD, DR & DME, mCNV, & RVO

Meta

Discover LUCENTIS® (ranibizumab) injection, a diabetic retinopathy & DME treatment option. See full safety for more information.

H1 Learn how to take action against vision loss from DR and DME

H3 Terms and Conditions

H3 This site is intended for US Healthcare Professionals

H3 Link to Third Party Site

H4 Important Safety Information & Indication

H5 What Are DR and DME?

H5 What Are the Risk Factors for DR and DME?

H5 About LUCENTIS for DR and DME

H5 I am a Healthcare Professional

H5 I am a Patient or Caregiver

📝 The Narrative — clean text per page (Info Density · Semantic Coherence)

HOMEPAGE (https://lucentis.com) LUCENTIS® (ranibizumab) a Treatment Option for wAMD, DR & DME, mCNV, & RVO

LUCENTIS® (ranibizumab injection)
[H2] For Patients and Caregivers

[IMG: LUCENTIS® (ranibizumab injection) for Patients and Caregivers]

Wet age-related macular degeneration (wet AMD)

Diabetic retinopathy and diabetic macular edema (DR and DME)

Myopic choroidal neovascularization (mCNV)

Macular edema following retinal vein occlusion (RVO)

LUCENTIS® (ranibizumab injection)
[H2] For US Healthcare Professionals

[IMG: LUCENTIS® (ranibizumab injection) for US Healthcare Professionals]

Wet age-related macular degeneration (wet AMD)

Diabetic retinopathy and diabetic macular edema (DR and DME)

Myopic choroidal neovascularization (mCNV)

Macular edema following retinal vein occlusion (RVO)

[H4] Learn more about your eye condition and how LUCENTIS may be able to help.
Over 12 million doses have been given since 2006.

LUCENTIS® (ranibizumab), a VEGF inhibitor, treats wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV).
LUCENTIS is designed to block vascular endothelial (VASS‐cue‐ler end‐oh‐THEEL‐e‐ull) growth factor, or VEGF (vej‐EFF), from inside the eye. This may help reduce unhealthy swelling, leaking, and growth of blood vessels, which helps maintain vision.
Lucentis is administered via intravitreal injection into the eye, typically performed monthly or as advised by your healthcare provider.
Serious risks such as infections, retinal detachments, or arterial thromboembolic events (ATEs) are rare. Monitoring intraocular pressure before and after treatment is essential. Seek immediate care if any severe vision changes or signs of infection occur.
Common side effects of LUCENTIS include conjunctival hemorrhage, eye pain, vitreous floaters, and intraocular pressure (IOP). Some individuals may also experience redness or discomfort after the injection.

[H4]
Important Safety Information

Back to Top

Who is LUCENTIS for? LUCENTIS® (ranibizumab injection) is a prescription medicine for the treatment of patients with:
wet age-related macular degeneration (wAMD)
macular edema following retinal vein occlusion (RVO)
diabetic macular edema (DME)
diabetic retinopathy (DR)
myopic choroidal neovascularization (mCNV)

What important safety information should I know about LUCENTIS? You should not use LUCENTIS if you have an infection in or around the eye or are allergic to LUCENTIS or any of its ingredients. LUCENTIS is a prescription medication given by injection into the eye, and it has side effects. Some LUCENTIS patients have had detached retinas and serious eye infections. If your eye becomes red, sensitive to light, or painful, or if you have a change in vision, call or visit your eye doctor right away.
Some LUCENTIS patients have had increases in eye pressure before and within 1 hour of an injection.
Uncommonly, LUCENTIS patients have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes. Fatal events were seen more often in patients with DME and DR with LUCENTIS compared with patients who did not receive LUCENTIS. Although there were only few fatal events which included causes of death typical of patients with advanced diabetic complications, these events may be caused by LUCENTIS.
Severe inflammation of vessels in the retina has happened for patients treated with LUCENTIS. Call your healthcare provider immediately if you experience a change in vision.
Some LUCENTIS patients have serious side effects related to the injection. These include serious infections inside the eye, detached retinas, and cataracts. The most common eye-related side effects are increased redness in the white of the eye, eye pain, small specks in vision, and increased eye pressure. The most common non–eye-related side effects are nose and throat infections, anemia, nausea and cough. Ask your doctor if you have questions or want more information.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.
For additional Safety Information, please talk to your doctor and see the LUCENTIS full Prescribing Information.

4423 chars

SUB-PAGE (https://lucentis.com/patient/safety.html) Safety

[H1] Important Safety Information

Who is LUCENTIS for? LUCENTIS® (ranibizumab injection) is a prescription medicine for the treatment of patients with:
wet age-related macular degeneration (wAMD)
macular edema following retinal vein occlusion (RVO)
diabetic macular edema (DME)
diabetic retinopathy (DR)
myopic choroidal neovascularization (mCNV)
What important safety information should I know about LUCENTIS? You should not use LUCENTIS if you have an infection in or around the eye or are allergic to LUCENTIS or any of its ingredients. LUCENTIS is a prescription medication given by injection into the eye, and it has side effects. Some LUCENTIS patients have had detached retinas and serious eye infections. If your eye becomes red, sensitive to light, or painful, or if you have a change in vision, call or visit your eye doctor right away.
Some LUCENTIS patients have had increases in eye pressure before and within 1 hour of an injection.
Uncommonly, LUCENTIS patients have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes. Fatal events were seen more often in patients with DME and DR with LUCENTIS compared with patients who did not receive LUCENTIS. Although there were only few fatal events which included causes of death typical of patients with advanced diabetic complications, these events may be caused by LUCENTIS.
Severe inflammation of vessels in the retina has happened for patients treated with LUCENTIS. Call your healthcare provider immediately if you experience a change in vision.
Some LUCENTIS patients have serious side effects related to the injection. These include serious infections inside the eye, detached retinas, and cataracts. The most common eye-related side effects are increased redness in the white of the eye, eye pain, small specks in vision, and increased eye pressure. The most common non–eye-related side effects are nose and throat infections, anemia, nausea and cough. Ask your doctor if you have questions or want more information.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.
For additional Safety Information, please talk to your doctor and see the LUCENTIS full Prescribing Information.

2315 chars

SUB-PAGE (https://lucentis.com/patient/wamd.html) Wet AMD Treatment Option | LUCENTIS® (ranibizumab)

[H1] Learn how to take action against vision loss from wet AMD

LUCENTIS is a prescription medicine for the treatment of wet age-related macular degeneration, or wet AMD. Explore this site to learn more about wet AMD, treatment, and what you may expect on your journey with LUCENTIS.

Financial Support

[H1] Learn how to take action against vision loss from wet AMD

Financial Support

[IMG: About Wet Age-Related Macular Degeneration (wAMD)]

[H5] What Is Wet AMD?

About wAMD

[IMG: Wet Age-Related Macular Degeneration (wAMD) and Vision]

[H5] How Does wAMD Affect
My Vision?

Learn More

[IMG: Image of LUCENTIS® (ranibizumab injection) prefilled syringe]

[H5] About LUCENTIS for wAMD

About LUCENTIS

Wet age-related macular degeneration (wet AMD) is a chronic eye condition that damages the macula, leading to vision loss caused by abnormal blood vessel growth. If left untreated, wet AMD may severely affect your vision.
LUCENTIS® (ranibizumab) is an FDA-approved medication that treats wet AMD, and is designed to block VEGF, which is responsible for the abnormal growth.
LUCENTIS is administered directly via intravitreal injections, typically once a month or as determined by your doctor. It helps preserve vision and manage the progress of wet AMD for eligible patients. Learn more about how wet AMD impacts vision and discuss your treatment options with your healthcare provider.
Serious risks such as infections, retinal detachments, or arterial thromboembolic events (ATEs) are rare. Monitoring intraocular pressure before and after treatment is essential. Seek immediate care if any severe vision changes or signs of infection occur.
Common side effects of LUCENTIS include conjunctival hemorrhage, eye pain, vitreous floaters, and intraocular pressure (IOP). Some individuals may also experience redness or discomfort after the injection.
Discover helpful resources and patient materials, including financial support options, to better navigate your wet AMD journey. Consult your doctor to see if LUCENTIS is the right treatment for you.

[H4]
Important Safety Information & Indication

Who is LUCENTIS for? LUCENTIS® (ranibizumab injection) is a prescription medicine for the treatment of patients with wet age-related macular degeneration (wAMD).

What important safety information should I know about LUCENTIS? You should not use LUCENTIS if you have an infection in or around the eye or are allergic to LUCENTIS or any of its ingredients. LUCENTIS is a prescription medication given by injection into the eye, and it has side effects. Some LUCENTIS patients have had detached retinas and serious eye infections. If your eye becomes red, sensitive to light, or painful, or if you have a change in vision, call or visit your eye doctor right away.
Some LUCENTIS patients have had increases in eye pressure before and within 1 hour of an injection.
Uncommonly, LUCENTIS patients have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes.
Severe inflammation of vessels in the retina has happened for patients treated with LUCENTIS. Call your healthcare provider immediately if you experience a change in vision.
Some LUCENTIS patients have serious side effects related to the injection. These include serious infections inside the eye, detached retinas, and cataracts. The most common eye-related side effects are increased redness in the white of the eye, eye pain, small specks in vision, and increased eye pressure. The most common non–eye-related side effects are nose and throat infections, anemia, nausea and cough. Ask your doctor if you have questions or want more information.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.
For additional Safety Information, please talk to your doctor and see the LUCENTIS full Prescribing Information.

4362 chars

SUB-PAGE (https://lucentis.com/patient/dr-dme.html) DR & DME Treatment Option | LUCENTIS® (ranibizumab)

[H1] Learn how to take action against vision loss from DR and DME

LUCENTIS is a prescription medicine for the treatment of diabetic retinopathy (DR) and diabetic macular edema (DME). Explore this site to learn more about DR, DME, treatment, and what you may expect on your journey with LUCENTIS.

Financial Support

[H1] Learn how to take action against vision loss from DR and DME

Financial Support

[IMG: About Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME)]

[H5] What Are DR and DME?

About DR and DME

[IMG: Risk Factors of Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME)]

[H5] What Are the Risk Factors
for DR and DME?

Learn More

[IMG: Image of LUCENTIS® (ranibizumab injection) prefilled syringe]

[H5] About LUCENTIS for
DR and DME

About LUCENTIS

Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME) are serious eye conditions caused by damage to the retina from diabetes, leading to vision loss. If untreated, DR and DME can progressively impair vision and significantly impact daily life. LUCENTIS® (ranibizumab) is an FDA-approved treatment for DR and DME, designed to target VEGF to reduce swelling, prevent further damage, and help maintain vision and slow the progression of your disease.
LUCENTIS is administered through intravitreal injections, typically on a monthly basis, or as decided by your doctor. Your treatment plan will depend on your condition and needs. Learn more about how DR and DME can affect vision and work with your healthcare provider to create a treatment approach to protect your eyesight.
Serious risks such as infections, retinal detachments, or arterial thromboembolic events (ATEs) are rare. Monitoring intraocular pressure before and after treatment is essential. Seek immediate care if any severe vision changes or signs of infection occur.
Common side effects of LUCENTIS include conjunctival hemorrhage, eye pain, vitreous floaters, and intraocular pressure (IOP). Some individuals may also experience redness or discomfort after the injection.
Explore helpful resources or connect with financial support programs for more information on managing your DR or DME. Ask your doctor if LUCENTIS is right for you.

[H4]
Important Safety Information & Indication

Who is LUCENTIS for? LUCENTIS® (ranibizumab injection) is a prescription medicine for the treatment of patients with diabetic retinopathy (DR) and diabetic macular edema (DME).

What important safety information should I know about LUCENTIS? You should not use LUCENTIS if you have an infection in or around the eye or are allergic to LUCENTIS or any of its ingredients. LUCENTIS is a prescription medication given by injection into the eye, and it has side effects. Some LUCENTIS patients have had detached retinas and serious eye infections. If your eye becomes red, sensitive to light, or painful, or if you have a change in vision, call or visit your eye doctor right away.
Some LUCENTIS patients have had increases in eye pressure before and within 1 hour of an injection.
Uncommonly, LUCENTIS patients have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes. Fatal events were seen more often in patients with DME and DR with LUCENTIS compared with patients who did not receive LUCENTIS. Although there were only few fatal events which included causes of death typical of patients with advanced diabetic complications, these events may be caused by LUCENTIS.
Severe inflammation of vessels in the retina has happened for patients treated with LUCENTIS. Call your healthcare provider immediately if you experience a change in vision.
Some LUCENTIS patients have serious side effects related to the injection. These include serious infections inside the eye, detached retinas, and cataracts. The most common eye-related side effects are increased redness in the white of the eye, eye pain, small specks in vision, and increased eye pressure. The most common non–eye-related side effects are nose and throat infections, anemia, nausea and cough. Ask your doctor if you have questions or want more information.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.
For additional Safety Information, please talk to your doctor and see the LUCENTIS full Prescribing Information.

4823 chars

🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)

0Review mentions (all pages)

0External proof links (all pages)

Page	Reviews	Proof links
/ (home)	0	0
/patient/safety.html	0	0
/patient/wamd.html	0	0
/patient/dr-dme.html	0	0

🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)

Homepage schema

{
    "@context": "http://schema.org",
    "@type": "Organization",
    "name": "Genentech",
    "url": "https://www.gene.com/",
    "logo": "https://www.gene.com/assets/frontend/img/Genentech_logo.png",
    "description": "Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases.",
    "contactPoint": {
        "@type": "ContactPoint",
        "telephone": "+1-877-436-3683",
        "contactType": "customer service"
    },
    "address": {
        "@type": "PostalAddress",
        "streetAddress": "1 DNA Way",
        "addressLocality": "South San Francisco",
        "addressRegion": "California",
        "postalCode": "94080",
        "addressCountry": "US"
    }
}

/patient/safety.html

{
    "@context": "http://schema.org",
    "@type": "Organization",
    "name": "Genentech",
    "url": "https://www.gene.com/",
    "logo": "https://www.gene.com/assets/frontend/img/Genentech_logo.png",
    "description": "Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases.",
    "contactPoint": {
        "@type": "ContactPoint",
        "telephone": "+1-877-436-3683",
        "contactType": "customer service"
    },
    "address": {
        "@type": "PostalAddress",
        "streetAddress": "1 DNA Way",
        "addressLocality": "South San Francisco",
        "addressRegion": "California",
        "postalCode": "94080",
        "addressCountry": "US"
    }
}

/patient/wamd.html

{
    "@context": "http://schema.org",
    "@type": "Organization",
    "name": "Genentech",
    "url": "https://www.gene.com/",
    "logo": "https://www.gene.com/assets/frontend/img/Genentech_logo.png",
    "description": "Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases.",
    "contactPoint": {
        "@type": "ContactPoint",
        "telephone": "+1-877-436-3683",
        "contactType": "customer service"
    },
    "address": {
        "@type": "PostalAddress",
        "streetAddress": "1 DNA Way",
        "addressLocality": "South San Francisco",
        "addressRegion": "California",
        "postalCode": "94080",
        "addressCountry": "US"
    }
}

/patient/dr-dme.html

{
    "@context": "http://schema.org",
    "@type": "Organization",
    "name": "Genentech",
    "url": "https://www.gene.com/",
    "logo": "https://www.gene.com/assets/frontend/img/Genentech_logo.png",
    "description": "Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases.",
    "contactPoint": {
        "@type": "ContactPoint",
        "telephone": "+1-877-436-3683",
        "contactType": "customer service"
    },
    "address": {
        "@type": "PostalAddress",
        "streetAddress": "1 DNA Way",
        "addressLocality": "South San Francisco",
        "addressRegion": "California",
        "postalCode": "94080",
        "addressCountry": "US"
    }
}

Your Diagnosis

Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.

Information Density 0 / 30

Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?

Semantic Coherence 0 / 20

Compare the homepage promise against the sub-page reality. Do they hold the same line?

Trust & Proof 0 / 20

Weigh review mentions against actual external proof links. Claims without verification = theatre.

Commodity Fingerprint 0 / 15

Check headings & narrative against the industry clichés in the setup above.

Identity & Authority 0 / 15

Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?

Your predicted BS score 0 / 100

💡 Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)

These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.

Information Density

Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.

Semantic Alignment

Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.

Trust & Proof

Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.

Commodity Fingerprint

Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.

Identity & Authority

Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.

Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.

BS Level

Medical Devices, Pharma & Biotech

40.8 Avg BS

Based on 587 businesses audited.

✓ Less BS than average

LUCENTIS (Genentech) has 14.8 points less BS than the average for Medical Devices, Pharma & Biotech.

BS Detector

Medical Devices, Pharma & Biotech BS: LUCENTIS (Genentech) (lucentis.com)

https://lucentis.com 📍 Industry: Medical Devices, Pharma & Biotech

26 BS / 100

Expert Verdict

This is a high-substance, low-fluff pharmaceutical portal that prioritize regulatory compliance over marketing flair. It is almost entirely devoid of traditional business bullshit, functioning instead as a legally-armored information repository. Its only significant BS-related issue is the massive textual repetition required by the FDA, which reduces overall information velocity.

Info Density Power-words vs. Substance ratio.

23% BS

Semantic Coherence Homepage promise vs. Sub-page reality.

10% BS

Trust & Proof Verifiable evidence vs. Trust Theatre.

30% BS

Commodity Fingerprint Detection of industry clichés/templates.

53% BS

Identity & Authority Expert verifiability & Schema depth.

20% BS

BS Reduction Prescription

Implement a dedicated Clinical Evidence page that links directly to peer-reviewed study abstracts or ClinicalTrials.gov identifiers. Add a descriptive H1 tag to the homepage to improve semantic structure and accessibility for screen readers. Include a more prominent link to the Full Prescribing Information PDF earlier in the user journey to bridge the proof gap. Reduce redundant text in sub-page hero sections by moving static safety blocks into a standardized footer to increase the substance-to-pixel ratio.

Industry Match & Score Summary

Industry Classification

The site is a textbook example of a branded pharmaceutical product portal for LUCENTIS (ranibizumab). It adheres strictly to regulatory communication standards for treatment options in ophthalmology including wAMD and DME.

“The low BS score of 26 is primarily driven by Information Density and Semantic Coherence, where the site provides specific medical metrics and perfect alignment between claims and delivery. Points were gained in the Commodity Fingerprint pillar due to the rigid, template-driven nature of pharma communication. Trust and Proof scores reflect the lack of direct external study links despite the high inherent authority of the Genentech brand.”

See Full BS Audit →

Analysis Disclosure & Source Attribution

This training module utilizes a snapshot of public data from LUCENTIS (Genentech), captured on May 31, 2026, to demonstrate how machine logic evaluates different types of business narratives.

Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.

Notice to LUCENTIS (Genentech): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.

Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.

To all users: You are encouraged to visit the live site at https://lucentis.com to view the most current version of its content and learn from the source what this company is about and what it offers.

Training Example: LUCENTIS (Genentech) – Review the Data, Give Your Score & Compare to the Real AI Evaluation